$ALKS 8-K SEC Filings

Filed On	Filing
21 Sep 2026	8-K: Regulation FD Disclosure; Other Events Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
16 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure DUBLIN, Sept. 16, 2026 — Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive...
12 Aug 2026	8-K: Entry into a Material Definitive Agreement
28 Jul 2026	8-K: Results of Operations and Financial Condition
08 Jul 2026	8-K: Termination of a Material Definitive Agreement
15 Jun 2026	8-K: Regulation FD Disclosure; Other Events
20 May 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
12 May 2026	8-K: Regulation FD Disclosure; Other Events
05 May 2026	8-K: Results of Operations and Financial Condition
25 Feb 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
25 Feb 2026	8-K: Results of Operations and Financial Condition
12 Feb 2026	8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
12 Jan 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
06 Jan 2026	8-K: Regulation FD Disclosure; Other Events
19 Nov 2025	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
12 Nov 2025	8-K: Regulation FD Disclosure; Other Events
28 Oct 2025	8-K: Results of Operations and Financial Condition
22 Oct 2025	8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
12 Sep 2025	8-K: Entry into a Material Definitive Agreement; Other Events
12 Sep 2025	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Comments